Skip to main content

Table 1 Antimicrobial susceptibility in Neisseria gonorrhoeae isolates (n = 522) from Minsk, Mogilev, and Vitebsk, Belarus, 2009–2019

From: Antimicrobial resistance in Neisseria gonorrhoeae isolates and gonorrhoea treatment in the Republic of Belarus, Eastern Europe, 2009–2019

Antimicrobials

Susceptible (S)/Susceptible, increased exposure (I)/Resistant (R), %a

 

2009b

2010-2011b

2012b

2013b

2014–2015

2017

2018–2019

Totalb

n = 81

n = 78

n = 75

n = 101

n = 73

n = 36

n = 78

n = 522

CRO

100/NA/0

100/NA/0

100/NA/0

100/NA/0

100/NA/0

100/NA/0

100/NA/0

100/NA/0

CFM

100/NA/0

100/NA/0

100/NA/0

98.0/NA/2.0

100/NA/0

77.8/NA/22.2

94.9/NA/5.1

97.3/NA/2.7

AZM

98.8/NA/1.2

100/NA/0

98.7/NA/1.3

100/NA/0

100/NA/0

100/NA/0

97.4/NA/2.6

99.2/NA/0.8

SPC

100/NA/0

100/NA/0

100/NA/0

100/NA/0

100/NA/0

100/NA/0

100/NA/0

100/NA/0

CIP

65.4/0/34.6

64.1/2.6/33.3

78.7/0/21.3

72.3/0/27.7

90.4/0/9.6

69.4/0/30.6

83.3/0/16.7

74.9/0.4/24.7

PEN

29.6/60.5/9.9

−/−/−

62.6/30.7/6.7

59.4/31.7/8.9

80.8/16.4/2.8

55.6/33.3/11.1

51.3/44.9/3.8

56.3/36.7/7.0

TET

55.5/21/23.5

56.4/10.3/33.3

56/9.3/34.7

62.4/8.9/28.7

76.7/5.5/17.8

69.4/0/30.6

61.5/11.5/26.9

61.9/10.3/27.8

GEN

72.8/27.2/0

97.4/2.6/0

58.7/41.3/0

40.6/59.4/0

67.1/32.9/0

55.6/44.4/0

87.2/12.8/0

68.4/31.6/0

  1. CRO Ceftriaxone, CFM Cefixime, AZM Azithromycin, SPC Spectinomycin, CIP Ciprofloxacin, PEN Benzylpenicillin, TET Tetracycline, GEN Gentamicin, NA Not applicable, −, not tested
  2. aThe clinical breakpoints (susceptible, resistant) were as follows: ceftriaxone and cefixime (MIC≤0.125 mg/L, MIC>0.125 mg/L), ciprofloxacin (MIC≤0.032 mg/L, MIC>0.064 mg/L), azithromycin (MIC≤1 mg/L, MIC>1 mg/L), spectinomycin (MIC≤64 mg/L, MIC>64 mg/L), benzylpenicillin (MIC≤0.064 mg/L, MIC>1.0 mg/L), tetracycline (MIC≤0.5 mg/L, MIC>1.0 mg/L), and gentamicin (MIC≤4 mg/L, MIC>16 mg/L) [47, 48].
  3. bOf the 335 isolates from 2009-2013, 273 have been previously published [39, 40]